Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Adult Spinal Muscular Atrophy (SMA) China Registry

Active, not recruiting

Conditions: Muscular Atrophy, Spinal

First Posted Date: 2022-11-16

Last Posted Date: 2024-06-21

Lead Sponsor: Biogen

Target Recruit Count: 200

Registration Number: NCT05618379

Locations: 🇨🇳
The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 9 locations

A Study to Learn About the Safety of Salanersen (BIIB115) Injections and How Salanersen is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

Phase 1

Active, not recruiting

Conditions: Healthy Volunteer
Muscular Atrophy, Spinal

Interventions: Drug: Salanersen
Drug: Salanersen-Matching Placebo

First Posted Date: 2022-10-12

Last Posted Date: 2025-05-14

Lead Sponsor: Biogen

Target Recruit Count: 62

Registration Number: NCT05575011

Locations: 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇨🇦
Children's Hospital of Eastern Ontario, Ontario, Canada
🇫🇷
Hôpital Armand Trousseau, Paris, France

and more 14 locations

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase 4

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Natalizumab

First Posted Date: 2022-09-08

Last Posted Date: 2024-06-21

Lead Sponsor: Biogen

Target Recruit Count: 1

Registration Number: NCT05532163

Locations: 🇩🇪
Neurologische Studiengesellschaft Bonn GbR, Bonn, Germany
🇩🇪
Neurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg, Germany

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

Phase 2

Recruiting

Conditions: Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus

Interventions: Drug: Litifilimab
Drug: Placebo

First Posted Date: 2022-09-08

Last Posted Date: 2025-05-11

Lead Sponsor: Biogen

Target Recruit Count: 474

Registration Number: NCT05531565

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
UAB Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States

and more 252 locations

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Phase 3

Terminated

Conditions: Parkinson Disease

Interventions: Drug: BIIB122
Drug: BIIB122-Matching Placebo

First Posted Date: 2022-06-14

Last Posted Date: 2024-06-26

Lead Sponsor: Biogen

Target Recruit Count: 7

Registration Number: NCT05418673

Locations: 🇺🇸
Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado, United States
🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

and more 24 locations

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Phase 2

Active, not recruiting

Conditions: Alzheimer's Disease Dementia
Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions: Drug: BIIB080
Drug: BIIB080-matching placebo

First Posted Date: 2022-06-01

Last Posted Date: 2025-05-18

Lead Sponsor: Biogen

Target Recruit Count: 416

Registration Number: NCT05399888

Locations: 🇺🇸
Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States
🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
🇺🇸
University of California San Francisco (PARENT), San Francisco, California, United States

and more 134 locations

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Phase 3

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Litifilimab
Drug: Litifilimab-matching placebo

First Posted Date: 2022-04-29

Last Posted Date: 2025-05-14

Lead Sponsor: Biogen

Target Recruit Count: 864

Registration Number: NCT05352919

Locations: 🇷🇴
S C Delta Health Care SRL, Bucuresti, Romania
🇺🇸
Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona, United States
🇺🇸
Wallace Rheumatic Study Center, Beverly Hills, California, United States

and more 137 locations

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy

Not Applicable

Completed

Conditions: Spinal Muscular Atrophy (SMA)

Interventions: Device: Virtual reality
Procedure: Standard of Care

First Posted Date: 2022-04-29

Last Posted Date: 2025-04-02

Lead Sponsor: Biogen

Target Recruit Count: 63

Registration Number: NCT05354414

Locations: 🇫🇷
Chu d' Angers, Angers, France
🇫🇷
CHRU de Brest, Brest, France
🇫🇷
Chu de Clermont Ferrand, Clermont Ferrand, France

and more 9 locations

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Phase 2

Active, not recruiting

Conditions: Parkinson Disease

Interventions: Drug: BIIB122-Matching Placebo
Drug: BIIB122

First Posted Date: 2022-04-27

Last Posted Date: 2025-05-04

Lead Sponsor: Biogen

Target Recruit Count: 650

Registration Number: NCT05348785

Locations: 🇫🇷
Hopital Henri Mondor, Paris, France
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States

and more 110 locations

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Aducanumab
Drug: Placebo

First Posted Date: 2022-04-04

Last Posted Date: 2025-04-23

Lead Sponsor: Biogen

Target Recruit Count: 1512

Registration Number: NCT05310071

Locations: 🇺🇸
K2 Medical Research, Orlando, Florida, United States
🇺🇸
Headlands Research LLC, Orlando, Florida, United States
🇺🇸
Conquest Research, Orlando, Florida, United States

and more 259 locations

Home Terms & Conditions Privacy Policy